Clinical trials: Patients with Advanced Solid Tumors
Solid Tumors
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
- Trial name
- NCT04250155
- Testing
- XmAb24306, Atezolizumab
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 195 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Lung Cancer
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
This is a multi-center, multi-cohort, open-label, phase Ib/II study to evaluate the efficacy, safety, PK characteristics, immunogenicity and potential biomarkers of AK105 monotherapy in the patients with selected advanced solid…
- Conditions
- Solid Tumor, Lung Cancer, HCC
- Trial name
- NCT04172506
- Testing
- AK105
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Akeso
Cancer, Solid Tumors
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans.
- Conditions
- Cancer, Solid Tumors, Lymphoma, Malignancy
- Trial name
- NCT01078649
- Testing
- Debio 1143 (AT-406)
- Where
- 3 sites in United States
- Volunteers
- 51 people
- Sponsor
- Debiopharm International SA
Advanced Malignant Solid Tumor
First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
This study is investigating a new experimental therapy, MP0317, a DARPin® drug candidate targeting fibroblast activation protein (FAP) and CD40.
- Trial name
- NCT05098405
- Testing
- MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q3w regimen), MP0317, a tri-specific fibroblast activation protein (FAP) x CD40 DARPin® drug candidate (q1w regimen)
- Where
- 4 sites in France, Netherlands
- Volunteers
- 46 people
- Sponsor
- Molecular Partners AG
Neoplasm
MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED)
The purposes of this phase I portion are; 1) to evaluate the safety and tolerability of MK2461 and 2) to determine the recommended phase 2 dose or doses of MK2461.
- Trial name
- NCT00496353
- Testing
- MK2461
- Volunteers
- 26 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Advanced Solid Tumour
A Study to Test Different Doses of BI 3968621 When Given Alone or With Ezabenlimab in Patients With Advanced Cancer
This study is open to adults with advanced cancer that cannot be removed by surgery or have spread to other parts of the body. The purpose of this study is to find the highest and most suitable dose of BI 3968621 that people with…
- Trial name
- NCT07851103
- Testing
- BI 3968621, ezabenlimab
- Where
- 10 sites in United States, Belgium and 3 more
- Volunteers
- 90 people
- Sponsor
- Boehringer Ingelheim
Neoplasms
A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors
Epothilone D represents one of a class of cytotoxic macrolides capable of causing mitotic arrest by stabilizing tubulin polymerization.
- Trial name
- NCT00030173
- Testing
- Epothilone D (KOS-862)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib
Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors
The purpose of this study is to evaluate the pharmacokinetics of 14C-labeled gilteritinib, in particular, the routes of excretion and extent of metabolism of gilteritinib following administration of a single dose of 14C-labeled…
- Trial name
- NCT02456883
- Testing
- gilteritinib, 14C-labeled gilteritinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02915523
- Testing
- entinostat, avelumab
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Syndax Pharmaceuticals
Solid Tumor, TNBC - Triple-Negative Breast Cancer
TH1902 in Patients With Advanced Solid Tumors
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard…
- Conditions
- Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer
- Trial name
- NCT04706962
- Testing
- TH1902
- Where
- 6 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- Theratechnologies
Advanced Solid Tumors
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
This study is a Phase I, dose escalation study of oral darinaparsin for the treatment of advanced solid tumors. Eligible patients could have received any amount of previous therapy.
- Trial name
- NCT01139346
- Testing
- darinaparsin
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Alaunos Therapeutics
Advanced Cancer, Metastatic Cancer
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
An open label, dose-escalation study to evaluate safety, tolerability, maximum tolerated dose (MTD), efficacy, and pharmacokinetics (PKs) of CPI-613 given twice weekly for three consecutive weeks in cancer patients The objectives…
- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors
- Trial name
- NCT00741403
- Testing
- CPI-613
- Where
- 4 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Cornerstone Pharmaceuticals
Advanced or Metastatic Solid Tumors, Cancer
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of SF1126 in patients with advanced or metastatic tumors by assessing the dose limiting toxicities (DLTs) and defining the maximum tolerated dose given twice…
- Conditions
- Advanced or Metastatic Solid Tumors, Cancer, Solid Cancers
- Trial name
- SF112600106 (NCT00907205)
- Testing
- SF1126
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Semafore Pharmaceuticals
Solid Tumor, Lymphoma, Non-Hodgkin
A Phase Ia Clinical Study of QLF31907 Injection in Patients With Advanced Malignant Tumors
This study is designed to evaluate the safety and tolerability of QLF31907 injection, to identify the maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), and determine the recommended phase Ib dose(RPIbD) and…
- Trial name
- NCT05150405
- Testing
- QLF31907
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Locally Advanced or Metastatic Solid Tumors
Clinical Study of SM3321 With Solid Tumors
The purpose of this study is to evaluate the Safety and Tolerability of SM3321 in patients with locally advanced or metastatic solid tumors
- Trial name
- NCT06087770
- Testing
- SM3321
- Where
- 3 sites in China
- Volunteers
- 7 people
- Sponsor
- Beijing StarMab Biomed Technology Ltd
Advanced or Metastatic Solid Tumors
Phase I of XKH002 Injection in Patients
This is a Phase 1, first-in-human (FIH), open-label, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of XKH002 in patients with advanced or…
- Trial name
- NCT06196762
- Testing
- XKH002 Injection
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Zhejiang Kanova Biopharmaceutical Co., LTD
Tumor, Solid, Cancer, Metastatic
Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors
This phase I trial is designed to efficiently identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) for the combination therapy regimen of the IDO1 inhibitor SHR9146 when administered in combination with…
- Conditions
- Tumor, Solid, Cancer, Metastatic, Neoplasm Malignant
- Trial name
- NCT03491631
- Testing
- SHR9146+SHR-1210, SHR9146+SHR-1210+Apatinib
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Cancer, Tumors
Detection of Tumor DNA in Blood Samples From Cancer Patients
The aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor nucleic acids in the blood of a cancer patient with diagnosed metastatic disease that is either commencing, currently…
- Trial name
- NCT02288754
- Testing
- Blood test
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Lexent Bio, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.